返回
摘要
En 中文
High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral oedema (HACE), and high-altitude pulmonary oedema (HAPE). The pathophysiology of these syndromes is not completely understood, although studies have substantially contributed to the current understanding of several areas. These areas include the role and potential mechanisms of brain swelling in AMS and HACE, mechanisms accounting for exaggerated pulmonary hypertension in HAPE, and the role of inflammation and alveolar-fluid clearance in HAPE. Only limited information is available about the genetic basis of high-altitude illness, and no clear associations between gene polymorphisms and susceptibility have been discovered. Gradual ascent will always be the best strategy for preventing high-altitude illness, although chemoprophylaxis may be useful in some situations. Despite investigation of other agents, acetazolamide remains the preferred drug for preventing AMS. The next few years are likely to see many advances in the understanding of the causes and management of high-altitude illness.
Keyword:
ACUTE MOUNTAIN-SICKNESS
ENDOTHELIAL GROWTH-FACTOR
HYPOXIC VENTILATORY RESPONSE
INHALED NITRIC-OXIDE
PULMONARY-EDEMA
CEREBRAL EDEMA
BRONCHOALVEOLAR LAVAGE
SIMULATED DESCENT
MODERATE ALTITUDE
CONTROLLED TRIAL
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
暂无机构信息
引用论文
Vascular endothelial growth factor is expressed in ovine pulmonary vascular smooth muscle cells in vitro and regulated by hypoxia and dexamethasone
PEDIATRIC RESEARCH
IF3.1
Islet Amyloid Polypeptide Response to Glucose, Insulin, and Somatostatin Analogue Administration
Diabetes
IF0

